飲んで効く薬の開発と適正使用に必要な技術と知識を身に付けよう
- 業績集(2013~現在) -

原著論文

1)  Kishimoto H, Miyazaki K, Takizawa Y, Shirasaka Y, Inoue K: Absorption-enhancing effect of nitric oxide on the absorption of hydrophobic drugs in rat duodenum. J Pharm Sci, 105, 729 – 733, 2016

2)  Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N: Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis, in press.

3)  Furukawa J, Inoue K, Maeda J, Yasujima T, Ohta K, Kanai Y, Takada T, Matsuo H, Yuasa H: Functional identification of SLC43A3 as an equilibrative nucleobase transporter involved in purine salvage in mammals. Sci. Rep, 5, 15057, 2015.

4)  Yamashiro T, Ohta K, Inoue K, Furumiya M, Hayashi Y, Yuasa H: Kinetic and time-dependent features of sustained inhibitory effect of myricetin on folate transport by proton-coupled folate transporter. Drug Metab Pharmacokinet, 30, 341 – 346, 2015.

5)  Jia Yin, Haichuan Duan, Yoshiyuki Shirasaka, Bhagwat Prasad, and Joanne Wang. Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins. Drug Metab Dispos, 43, 1872 – 1881, 2015.

6)  Amarjit S. Chaudhry, Bhagwat Prasad, Yoshiyuki Shirasaka, Alie Fohner, David Finkelstein, Yiping Fan, Shuoguo Wang, Gang Wu*1, Eleni Aklillu, Sarah Sim, Magnus Ingelman-Sundberg, Kenneth E. Thummel, and Erin G. Schuetz. The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug Metab Dispos, 43, 1226 – 1235, 2015.

7)  Mimura Y, Yasujima T, Ohta K, Inoue K, Yuasa H: Functional identification of organic cation transporter 1 as an atenolol transporter sensitive to flavonoids. Biochemistry and Biophysics Reports, 2, 166 – 171, 2015.

8)  Furumiya M, Yamashiro T, Inoue K, Nishijima C, Ohta K, Hayashi Y, Yuasa H: Sustained inhibition of proton-coupled folate transporter by myricetin. Drug Metab Pharmacokinet, 30, 154 – 159, 2015.

9)  Inoue K, Yuasa H: Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet, 29, 12 – 19, 2014.

10)  Katano T, Ito Y, Ohta K, Yasujima T, Inoue K, Yuasa H: Competitive inhibition of AQP7-mediated glycerol transport by glycerol derivatives. Drug Metab Pharmacokinet, 29, 348 – 351, 2014.

11)  Furumiya M, Inoue K, Nishijima C, Yamashiro T, Inaoka E, Ohta K, Hayashi Y, Yuasa H: Noncompetitive inhibition of proton-coupled folate transporter by myricetin. Drug Metab Pharmacokinet, 29, 312 – 316, 2014.

12)  Nakada T, Kito T, Inoue K, Masuda S, Inui K, Matsubara K, Moriyama Y, Hisanaga N, Adachi Y, Suzuki M, Yamada I, Kusuhara H: Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine. Drug Metab Pharmacokinet, 29, 266 – 271, 2014.

13)  Katano T, Ito Y, Ohta K, Yasujima T, Inoue K, Yuasa H: Functional characteristics of aquaporin 7 as a facilitative glycerol carrier. Drug Metab Pharmacokinet, 29, 244 – 248, 2014.

14)  Nabokina SM, Inoue K, Subramanian VS, Valle JE, Yuasa H, Said HM: Molecular identification and functional characterization of the human colonic thiamine pyrophosphate transporter. J Biol Chem, 289, 4405 – 4416, 2014.

15)  Kato K, Mori H, Kito T, Yokochi M, Ito S, Inoue K, Yonezawa A, Katsura T, Kumagai Y, Yuasa H, Moriyama Y, Inui K, Kusuhara H, Sugiyama Y: Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins. Pharm Res, 31, 136-147. 2014.

16)  Nakayama A, Matsuo H, Shimizu T, Ogata H, Takada Y, Nakashima H, Nakamura T, Shimizu S, Chiba T, Sakiyama M, Ushiyama C, Takada T, Inoue K, Kawai S, Hishida A, Wakai K, Hamajima N, Ichida K, Sakurai Y, Kato Y, Shimizu T, Shinomiya N: A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. Hum Cell. 26, 133 – 136, 2013.

17)  Imamura Y, Murayama N, Okudaira N, Kurihara A, Inoue K, Yuasa H, Izumi T, Kusuhara H, Sugiyama Y: Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects. Pharm Res, 30, 447 – 457, 2013.

18)  Furumiya M, Inoue K, Ohta K, Hayashi Y, Yuasa H: Transcriptional regulation of PCFT by KLF4, HNF4α, CDX2 and C/EBPα: implication in its site-specific expression in the small intestine. Biochem Biophys Res Commun. 431, 158 – 163, 2013.

 総説(和文)

1)  井上勝央:フラボノイド配糖体の吸収機構.FFJ ジャーナル,218, 251 – 257, 2013

2)  井上勝央,湯浅博昭:メトトレキサートによる関節リウマチ治療と葉酸トランスポーター.医学のあゆみ,245, 127-132, 2013.

  • 東京薬科大学薬学部HOME
  • 東京薬科大学薬学部医療薬学科
  • 東京薬科大学薬学部医療薬物薬学科
  • 東京薬科大学薬学部医療衛生薬学科
研究室の業績
NEWSカテゴリ-
  • カテゴリーなし